3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Cyclobenzaprine.
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gamma Hydroxybutyric Acid.
Abiraterone
The serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.
Advertisement
Acenocoumarol
Cyclobenzaprine may increase the anticoagulant activities of Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.
Advertisement
Acetophenazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acetophenazine.
Albuterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.
Alfaxalone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.
Advertisement
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclobenzaprine.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.
Alogliptin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Alogliptin.
alpha 1-Antitrypsin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alpha 1-Proteinase Inhibitor, Human
The serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alphaprodine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.
Altretamine
Altretamine may increase the orthostatic hypotensive activities of Cyclobenzaprine.
Amiodarone
The metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine.
Amobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Amobarbital.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.
Amphetamine
Cyclobenzaprine may increase the serotonergic activities of Amphetamine.
Amprenavir
The serum concentration of Cyclobenzaprine can be increased when it is combined with Amprenavir.
Antithrombin III
The serum concentration of Cyclobenzaprine can be increased when it is combined with Antithrombin III human.
Antithrombin III, Human
The serum concentration of Cyclobenzaprine can be increased when it is combined with Antithrombin III human.
Apalutamide
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.
Apomorphine
Cyclobenzaprine may decrease the antihypertensive activities of Apomorphine.
Apraclonidine
Cyclobenzaprine may decrease the antihypertensive activities of Apraclonidine.
Aprepitant
The serum concentration of Cyclobenzaprine can be increased when it is combined with Aprepitant.
Aprotinin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.
Arbutamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arbutamine.
Arformoterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arformoterol.
Argatroban
The serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.
Argatroban Anhydrous
The serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.
Aripiprazole
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.
Artemether
The metabolism of Cyclobenzaprine can be decreased when combined with Artemether.
Articaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.
Asunaprevir
The serum concentration of Cyclobenzaprine can be increased when it is combined with Asunaprevir.
Atazanavir
The metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.
Azelastine
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azithromycin
The metabolism of Cyclobenzaprine can be decreased when combined with Azithromycin.
Baclofen
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Baclofen.
Bambuterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bambuterol.
Barbexaclone
The metabolism of Cyclobenzaprine can be increased when combined with Barbexaclone.
Barbital
The metabolism of Cyclobenzaprine can be increased when combined with Barbital.
Benazepril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.
Benoxinate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.
Benzphetamine
Cyclobenzaprine may decrease the antihypertensive activities of Benzphetamine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.
Betaxolol
The metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.
Bethanidine
Cyclobenzaprine may decrease the antihypertensive activities of Bethanidine.
Bivalirudin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.
Boceprevir
The metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.
Brexpiprazole
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Bromazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.
Bromocriptine
Cyclobenzaprine may decrease the antihypertensive activities of Bromocriptine.
Bromperidol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.
Brotizolam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bupivacaine.
Buprenorphine
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.
Butalbital
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.
Butamben
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.
Caffeine
The metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.
Captopril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.
Carbamazepine
The metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.
Cariprazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cariprazine.
Carisoprodol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.
Celecoxib
The metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.
Celiprolol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Celiprolol.
Ceritinib
The serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.
Chlormethiazole
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.
Chloroquine
The metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.
Chlorpromazine
The metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.
Cholecalciferol
The metabolism of Cyclobenzaprine can be decreased when combined with Cholecalciferol.
Cholesterol
The serum concentration of Cyclobenzaprine can be increased when it is combined with Cholesterol.
Cilastatin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Cilastatin.
Cilazapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.
Cimetidine
The metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.
Cinacalcet
The serum concentration of Cyclobenzaprine can be increased when it is combined with Cinacalcet.
Citalopram
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.
Clarithromycin
The metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.
Clenbuterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.
Clidinium
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.
Clidinium bromide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.
Clobazam
The metabolism of Cyclobenzaprine can be decreased when combined with Clobazam.
Clomipramine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.
Clonidine
Cyclobenzaprine may decrease the antihypertensive activities of Clonidine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.
Clotrimazole
The metabolism of Cyclobenzaprine can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Cyclobenzaprine can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Cyclobenzaprine can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Cyclobenzaprine.
Crizotinib
The metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.
Cyamemazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyamemazine.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.
Cyclosporine
The metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.
Cyproterone Acetate
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.
Dabrafenib
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.
Dapiprazole
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.
Darifenacin
The metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Cyclobenzaprine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.
Desipramine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.
Desmopressin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.
Dexmedetomidine
Cyclobenzaprine may decrease the antihypertensive activities of Dexmedetomidine.
Dexmethylphenidate
The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Cyclobenzaprine.
Dextroamphetamine
Cyclobenzaprine may increase the stimulatory activities of Dextroamphetamine.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.
Dextromoramide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.
Dibucaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cinchocaine.
Dicumarol
Cyclobenzaprine may increase the anticoagulant activities of Dicoumarol.
Diethylpropion
Cyclobenzaprine may increase the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Difenoxin.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.
Dihydroergotamine
Cyclobenzaprine may decrease the antihypertensive activities of Dihydroergotamine.
Diltiazem
The metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.
Diphenhydramine
The metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.
Dipivefrin
Cyclobenzaprine may decrease the antihypertensive activities of Dipivefrin.
Dobutamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.
Dolasetron
Dolasetron may increase the serotonergic activities of Cyclobenzaprine.
Dothiepin
The metabolism of Cyclobenzaprine can be decreased when combined with Dosulepin.
Doxepin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.
Doxycycline
The metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Dronedarone
The metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Droxidopa
Cyclobenzaprine may decrease the antihypertensive activities of Droxidopa.
Duloxetine
Duloxetine may increase the serotonergic activities of Cyclobenzaprine.
Dyclonine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine.
Edoxaban
The serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.
Efavirenz
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.
Eliglustat
The metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.
Enalapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.
Enalaprilat
The serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.
Enalaprilat Anhydrous
The serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.
Enflurane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.
Enzalutamide
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.
Epigallocatechin Gallate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Epigallocatechin Gallate.
Epinephrine
Cyclobenzaprine may decrease the antihypertensive activities of Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.
Ergonovine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.
Ergotamine
Cyclobenzaprine may decrease the antihypertensive activities of Ergotamine.
Erythromycin
The metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.
Estazolam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.
Ethanol
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.
Ethotoin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etifoxine.
Etomidate
Cyclobenzaprine may decrease the antihypertensive activities of Etomidate.
Ezogabine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.
Fenoterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.
Fexofenadine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.
Fibrinolysis Inhibitor
The serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.
Flibanserin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.
Fluconazole
The metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.
Fluindione
Cyclobenzaprine may increase the anticoagulant activities of Fluindione.
Flunarizine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.
Flunitrazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.
Fluoxetine
The risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.
Fluspirilene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone propionate.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyclobenzaprine.
Formoterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Formoterol.
Fosamprenavir
The serum concentration of Cyclobenzaprine can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Cyclobenzaprine can be increased when it is combined with Fosaprepitant.
Fosinopril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.
Fosphenytoin
The metabolism of Cyclobenzaprine can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Frovatriptan.
Furazolidone
Cyclobenzaprine may increase the serotonergic activities of Furazolidone.
Fusidate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin Enacarbil.
Glutethimide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Glutethimide.
Granisetron
Granisetron may increase the serotonergic activities of Cyclobenzaprine.
Guanabenz
Cyclobenzaprine may decrease the antihypertensive activities of Guanabenz.
Guanfacine
Cyclobenzaprine may decrease the antihypertensive activities of Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halazepam.
Haloperidol
The metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.
Halothane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Heroin.
Hexobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Hexobarbital.
Hydrocodone
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Hypoxis hemerocallidea root extract
The metabolism of Cyclobenzaprine can be increased when combined with St. John's Wort.
Idelalisib
The metabolism of Cyclobenzaprine can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.
Imatinib
The metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.
Imidapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.
Indacaterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.
Indinavir
The metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.
Iproniazid
Cyclobenzaprine may increase the serotonergic activities of Iproniazid.
Isavuconazole
The serum concentration of Cyclobenzaprine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazonium.
Isocarboxazid
The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Isocarboxazid.
Isoetharine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclobenzaprine.
Isoflurophate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.
Isoniazid
The metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.
Isoproterenol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.
Isradipine
The metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.
Ixazomib
The serum concentration of Cyclobenzaprine can be increased when it is combined with Ixazomib.
Ketamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.
Ketazolam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.
Ketoconazole
The metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.
Lamotrigine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.
Lepirudin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.
Levalbuterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levosalbutamol.
Levetiracetam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.
Levobupivacaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.
Levodopa
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.
Levonordefrin
Cyclobenzaprine may decrease the antihypertensive activities of Levonordefrin.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.
Levothyroxine
Levothyroxine may increase the arrhythmogenic activities of Cyclobenzaprine.
Lidocaine
The metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.
Linagliptin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Linagliptin.
Linezolid
Linezolid may increase the serotonergic activities of Cyclobenzaprine.
Liothyronine
Liothyronine may increase the arrhythmogenic activities of Cyclobenzaprine.
Lisdexamfetamine
Cyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Cyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.
Lisinopril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.
Lisinopril Anhydrous
The serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.
Lithium
Lithium may increase the neurotoxic activities of Cyclobenzaprine.
Lithium Cation
Lithium may increase the neurotoxic activities of Cyclobenzaprine.
Lofexidine
Cyclobenzaprine may decrease the antihypertensive activities of Lofexidine.
Lopinavir
The metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.
Lorcaserin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lormetazepam.
Lovastatin
The metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobenzaprine.
Luliconazole
The serum concentration of Cyclobenzaprine can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Cyclobenzaprine can be increased when combined with Lumacaftor.
Lumefantrine
The metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.
Magnesium Sulfate
The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Magnesium sulfate.
Manidipine
The metabolism of Cyclobenzaprine can be decreased when combined with Manidipine.
Maprotiline
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.
Meclizine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.
Melatonin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.
Mephentermine
Cyclobenzaprine may increase the vasopressor activities of Mephentermine.
Mephobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.
Mesoridazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.
Metaproterenol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Orciprenaline.
Metaraminol
Cyclobenzaprine may increase the vasopressor activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadyl Acetate.
Methamphetamine
Cyclobenzaprine may decrease the antihypertensive activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.
Methohexital
The metabolism of Cyclobenzaprine can be increased when combined with Methohexital.
Methotrimeprazine
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxamine
Cyclobenzaprine may increase the vasopressor activities of Methoxamine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.
Methylene blue
Cyclobenzaprine may increase the serotonergic activities of Methylene blue.
Methylphenidate
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyclobenzaprine.
Metoprolol
The metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melperone.
Metyrosine
Cyclobenzaprine may increase the sedative activities of Metyrosine.
Mexiletine
The metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.
Midodrine
Cyclobenzaprine may increase the vasopressor activities of Midodrine.
Midostaurin
The metabolism of Cyclobenzaprine can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Cyclobenzaprine can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.
Minaprine
Cyclobenzaprine may increase the serotonergic activities of Minaprine.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Mirabegron
The metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.
Mirtazapine
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.
Moclobemide
Cyclobenzaprine may increase the serotonergic activities of Moclobemide.
Moexipril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.
Molindone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.
Moxonidine
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Cyclobenzaprine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.
Naphazoline
Cyclobenzaprine may decrease the antihypertensive activities of Naphazoline.
Naratriptan
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naratriptan.
Nefazodone
The metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Cyclobenzaprine can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Cyclobenzaprine can be increased when combined with Nevirapine.
Nialamide
Cyclobenzaprine may increase the serotonergic activities of Nialamide.
Nicardipine
The metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.
Nicorandil
Cyclobenzaprine may increase the hypotensive activities of Nicorandil.
Nilotinib
The metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.
Nitrazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrous oxide.
Norepinephrine
Cyclobenzaprine may decrease the antihypertensive activities of Norepinephrine.
Norflurane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclobenzaprine.
O-PHENANTHROLINE
The serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.
Olaparib
The metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.
Olodaterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olodaterol.
Olopatadine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.
Ondansetron
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Opium.
Orphenadrine
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Cyclobenzaprine can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.
Oxprenolol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.
Oxymetazoline
Cyclobenzaprine may decrease the antihypertensive activities of Oxymetazoline.
Oxymorphone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.
p-Hydroxyamphetamine
Cyclobenzaprine may increase the stimulatory activities of Hydroxyamphetamine.
Palbociclib
The serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.
Paliperidone
Cyclobenzaprine may decrease the antihypertensive activities of Paliperidone.
Palonosetron
Palonosetron may increase the serotonergic activities of Cyclobenzaprine.
Panobinostat
The serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.
Paraldehyde
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.
Pargyline
Cyclobenzaprine may increase the serotonergic activities of Pargyline.
Paroxetine
The risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.
Peginterferon Alfa-2b
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.
Pentobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Perazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perazine.
Pergolide
Cyclobenzaprine may decrease the antihypertensive activities of Pergolide.
Periciazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.
Perindopril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobenzaprine.
Phenelzine
Cyclobenzaprine may increase the serotonergic activities of Phenelzine.
Phenindione
Cyclobenzaprine may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoxyethanol.
Phenprocoumon
Cyclobenzaprine may increase the anticoagulant activities of Phenprocoumon.
Phentermine
Cyclobenzaprine may increase the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Cyclobenzaprine may increase the stimulatory activities of Phentermine.
Phenylephrine
Cyclobenzaprine may increase the vasopressor activities of Phenylephrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenylpropanolamine.
Phenytoin
The metabolism of Cyclobenzaprine can be increased when combined with Phenytoin.
Pimozide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.
Pipamperone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.
Pirbuterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pirbuterol.
Pirinitramide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.
Posaconazole
The metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.
Pramipexole
Cyclobenzaprine may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Cyclobenzaprine can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prilocaine.
Primidone
The metabolism of Cyclobenzaprine can be increased when combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaine.
Procarbazine
Cyclobenzaprine may increase the serotonergic activities of Procarbazine.
Procaterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaterol.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.
Promazine
The metabolism of Cyclobenzaprine can be decreased when combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.
Proparacaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Proparacaine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.
Propoxyphene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextropropoxyphene.
Prothipendyl
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prothipendyl.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.
Pseudoephedrine
Cyclobenzaprine may decrease the antihypertensive activities of Pseudoephedrine.
Quazepam
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.
Quetiapine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.
Quinapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.
Quinidine
Cyclobenzaprine may increase the QTc-prolonging activities of Quinidine.
Quinine
The metabolism of Cyclobenzaprine can be decreased when combined with Quinine.
Racecadotril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Racecadotril.
Ramelteon
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.
Ramipril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.
Ranolazine
The metabolism of Cyclobenzaprine can be decreased when combined with Ranolazine.
Rasagiline
Cyclobenzaprine may increase the serotonergic activities of Rasagiline.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.
Remoxipride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Cyclobenzaprine.
Rifabutin
The metabolism of Cyclobenzaprine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.
Risperidone
Cyclobenzaprine may decrease the antihypertensive activities of Risperidone.
Ritodrine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.
Ritonavir
The metabolism of Cyclobenzaprine can be decreased when combined with Ritonavir.
Rivaroxaban
The serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.
Rizatriptan
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rizatriptan.
Rolapitant
The metabolism of Cyclobenzaprine can be decreased when combined with Rolapitant.
Ropinirole
Cyclobenzaprine may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ropivacaine.
Rotigotine
Cyclobenzaprine may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Cyclobenzaprine can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclobenzaprine.
Salmeterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salmeterol.
Saquinavir
The metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Cyclobenzaprine can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Saxagliptin.
Saxagliptin Anhydrous
The serum concentration of Cyclobenzaprine can be increased when it is combined with Saxagliptin.
Scopolamine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.
Secobarbital
The metabolism of Cyclobenzaprine can be increased when combined with Secobarbital.
Selegiline
Cyclobenzaprine may increase the serotonergic activities of Selegiline.
Sertindole
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.
Sertraline
The risk or severity of adverse effects can be increased when Sertraline is combined with Cyclobenzaprine.
Sevoflurane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.
Sildenafil
The metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Cyclobenzaprine can be increased when it is combined with Simeprevir.
Sitagliptin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.
Sitagliptin Phosphate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Sodium Phosphate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium phosphate.
Sodium Phosphate, Monobasic
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium phosphate.
Spirapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.
ST. JOHN'S WORT EXTRACT
The metabolism of Cyclobenzaprine can be increased when combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.
Sulfisoxazole
The metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.
Suvorexant
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Tasimelteon
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tasimelteon.
Tedizolid
Tedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.
Tedizolid Phosphate
Tedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.
Telaprevir
The metabolism of Cyclobenzaprine can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.
Tenofovir Disoproxil
The metabolism of Cyclobenzaprine can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.
Terbutaline
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.
Teriflunomide
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.
Tetrabenazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
Thalidomide
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.
Thiamylal
The metabolism of Cyclobenzaprine can be increased when combined with Thiamylal.
Thiopental
The metabolism of Cyclobenzaprine can be increased when combined with Thiopental.
Thiopental Sodium
The metabolism of Cyclobenzaprine can be increased when combined with Thiopental.
Thioproperazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.
Thioridazine
The metabolism of Cyclobenzaprine can be decreased when combined with Thioridazine.
Thiothixene
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.
Thyroid, Porcine
Thyroid, porcine may increase the arrhythmogenic activities of Cyclobenzaprine.
Tiagabine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.
Tiapride
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.
Ticlopidine
The metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.
Tipranavir
The metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.
Tizanidine
Cyclobenzaprine may decrease the antihypertensive activities of Tizanidine.
Tocilizumab
The serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.
Tolcapone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.
Toloxatone
Cyclobenzaprine may increase the serotonergic activities of Toloxatone.
Topiramate
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.
Tramadol
Cyclobenzaprine may increase the neuroexcitatory activities of Tramadol.
Trandolapril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.
Tranylcypromine
Cyclobenzaprine may increase the serotonergic activities of Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.
Triazulenone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.
Triflupromazine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclobenzaprine.
Triprolidine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.
Tropisetron
Tropisetron may increase the serotonergic activities of Cyclobenzaprine.
Urethane
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.
Valproate
The serum concentration of Cyclobenzaprine can be increased when it is combined with Valproic Acid.
Valproic Acid
The serum concentration of Cyclobenzaprine can be increased when it is combined with Valproic Acid.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cyclobenzaprine.
Venlafaxine
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine.
Verapamil
The metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vigabatrin.
Vilanterol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilanterol.
Vilazodone
The risk or severity of adverse effects can be increased when Vilazodone is combined with Cyclobenzaprine.
Vildagliptin
The serum concentration of Cyclobenzaprine can be increased when it is combined with Vildagliptin.
Voriconazole
The metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclobenzaprine.
Warfarin
Cyclobenzaprine may increase the anticoagulant activities of Warfarin.
Xylometazoline
Cyclobenzaprine may decrease the antihypertensive activities of Xylometazoline.
Yohimbine
The serum concentration of Yohimbine can be increased when it is combined with Cyclobenzaprine.
Zaleplon
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.
Ziconotide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.
Ziprasidone
The metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.
Zofenopril
The serum concentration of Cyclobenzaprine can be increased when it is combined with Zofenopril.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine.
Zolpidem
Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.
Zopiclone
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zopiclone.
Zotepine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.
